Renal endpoints in renal and cardiovascular randomized clinical trials: Time for a consensus?

Fundamental and Clinical Pharmacology

Volumn 26, Issue 6, 2012, Pages 771-782

  Halimi, Jean Michel ^a   Sautenet, Bénédicte ^b   Gatault, Philippe ^b   Roland, Mélanie ^b   Giraudeau, Bruno ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Clinical trials; Composite endpoints; Nephroprotection; Renal trials; Surrogate endpoints

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AST 120; AVOSENTAN; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BICARBONATE; EPRODISATE; IRBESARTAN; LOSARTAN; METOPROLOL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ALBUMINURIA; AMYLOIDOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONSENSUS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE MARKER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ENDPOINT; RENAL PROTECTION; RISK REDUCTION; SYSTEMATIC REVIEW; VALIDITY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DRUGS, INVESTIGATIONAL; ENDPOINT DETERMINATION; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867985461     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00965.x     Document Type: Article

References (31)

1. Spence D. Bad medicine: chronic kidney disease. BMJ (2010) 340 3188.
2. Bakris G.L., Sarafidis P.A., Weir M.R. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (2010) 375 1173-1181.
3. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. (2007) 49(2 Suppl 2) S74-S87.
4. Bakris G.L., Toto R.D., McCullough P.A. et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. (2008) 73 1303-1309.
5. Kunz R., Friedrich C., Wolbers M., Mann J.F.E. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. (2008) 148 30-48.
6. Mann J.F.E., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind controlled trial. Lancet (2008) 372 547-553.
7. Ruggenenti P., Fassi A., Ilieva A.P. et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. (2004) 351 1941-1951.
8. Bastiaan E., de Galan B.E., Perkovic V. et al. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. (2009) 20 883-892.
9. Mauer M., Zinman B., Gardiner R. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. (2009) 361 40-45.
10. Bilous R., Chaturvedi N., Sjølie A.K. et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Three randomized trials. Ann. Intern. Med. (2009) 151 11-20.
11. Dream Trial investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care (2008) 31 1007-1014.
12. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. (1989) 8 431-440.
13. Stevens L.A., Greene T., Levey A.S. Surrogate endpoints for clinical trials of kidney disease progression. Clin. J. Am. Soc. Nephrol. (2006) 1 874-884.
14. Lerche la Cour J., Brok J., Gotzsche P. Inconsistent reporting of surrogate outcomes in randomized clinical trials. BMJ (2010) 341 c3653. doi: 10.1136/bmj.c3653.
15. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials. Greater precision but with greater uncertainty?. JAMA (2003) 289 2554-2559.
16. Casas J.P., Chua W., Loukogeorgakis S. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet (2005) 366 2026-2033.
17. Bucher H.C., Guyatt G.H., Cook D.J., Holbrook A., McAlister F.A. User's guides to the medical literature. XIX. Applying clinical trial results. How to use an article measuring the effect of an intervention on surrogate endpoints. JAMA (1999) 282 771-778.
18. Perkins B.A., Krolewski A.S. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr. Opin. Nephrol. Hypertens. (2009) 18 233-240.
19. Mann J.F.E., Schmieder R.E., Dyal L. et al. Effect of telmisartan on renal outcomes. A randomized trial. Ann. Intern. Med. (2009) 151 1-10.
20. Hsu C.Y. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials J. Hum. Hypertens. (2001) 15 99-106.
21. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. (2001) 345 851-860.
22. Wright J.T. Jr, Bakris G., Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 288 2421-2431.
23. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. (2010) 362 1575-1585.
24. Rahman M., Pressel S., Davis B.R. et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. Arch. Intern. Med. (2005) 165 936-946.
25. Montori V.M., Permanyer-Miralda G., Ferreira-Gonzalez I. et al. Validity of composite endpoints in clinical trials. BMJ (2005) 330 594-596.
26. Cordoba G., Schartz L., Woloshin S., Bae H., Gotzsche P. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ (2010) 341 c3920. doi: 10.1136/bmj.c3920.
27. Levey A.S., Cattran D., Friedman A. et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national kidney foundation and the US food and drug administration. Am. J. Kidney Dis. (2009) 54 205-226.
28. Haller H., Viberti G.C., Mimran A. et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the randomised olmesartan and diabetes microalbuminuria prevention study. J. Hypertens. (2006) 24 403-408.
29. Weir M.R., Bakris G.L. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. Am. J. Nephrol. (2010) 31 469-470.
30. Ruilope L., Segura J., Fujita T., Ritz E. Renal and cardiovascular events: do they deserve the same consideration in clinical trials? J. Hypertens. (2009) 27 1743-1745.
31. Goldsmith CH., Boers M., Bombardier C. et al. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J. Rheumatol. (1993) 20 561-565.